|
| Variable | Number | Percent |
|
| Where information first obtained on CDC’s MDDR | | |
| CDC website | 1/35 | 3 |
| “Dear Colleague” letter | 6/35 | 18 |
| Conference call with CDC | 3/35 | 9 |
| Professional meeting | 9/35 | 26 |
| Regional Training and Medical Consultation Center (RTMCC) | 0/35 | 0 |
| TB control program | 7/35 | 20 |
| Another public health laboratory | 1/35 | 3 |
| CDC TB laboratory consultant | 8/35 | 23 |
| Initiates requests for using CDC’s MDDR | | |
| Health care provider | 12/35 | 34 |
| TB control program | 25/35 | 71 |
| Laboratory | 17/35 | 49 |
| Laboratory only after consultation with program staff | 10/35 | 29 |
| Other | 2/35 | 6 |
| Satisfaction with turnaround time for receiving results from CDC’s MDDR | | |
| Very satisfied | 26/35 | 74 |
| Satisfied | 8/35 | 23 |
| Neither satisfied nor dissatisfied | 1/35 | 3 |
| Dissatisfied | 0/35 | 0 |
| Very dissatisfied | 0/35 | 0 |
| Usual time frame to report molecular results from CDC’s MDDR to health care providers | | |
| Reported within one business day | 21/35 | 60 |
| Reported within two business days | 5/35 | 14 |
| Reporting time varies depending on circumstances | 1/35 | 3 |
| Results are reported to health care provider by TB control program | 8/35 | 23 |
| Not applicable. Health care provider receives separate report from CDC’s MDDR | 0/35 | 0 |
| Withhold reporting molecular results from CDC’s MDDR to health care providers until phenotypic DST is completed by CDC | | |
| Yes | 0/35 | 0 |
| Sometimes | 0/35 | 0 |
| No, results reported as soon as possible | 30/35 | 86 |
| Not applicable. Results are reported to health care provider by TB control program | 5/35 | 14 |
| Not applicable. Health care provider receives separate report from CDC’s MDDR | 0/35 | 0 |
| Withhold reporting molecular results from CDC’s MDDR to health care providers until phenotypic DST is completed by your laboratory | | |
| Yes | 0/35 | 0 |
| Sometimes | 0/35 | 0 |
| No, molecular results reported as soon as possible | 29/35 | 83 |
| Not applicable. Results are reported to health care provider by TB control program | 6/35 | 17 |
| Not applicable. Health care provider receives separate report from CDC’s MDDR | 0/35 | 0 |
| Method (s) for reporting results from CDC’s MDDR to health care providers | | |
| Verbally | 9/35 | 26 |
| Copy of CDC report is provided | 31/35 | 89 |
| CDC results transcribed into LIMS for reporting | 1/35 | 3 |
| Not applicable. Results are not reported by our laboratory | 3/35 | 9 |
| Comparison of molecular results from CDC’s MDDR with own phenotypic DST for first-line drugs | | |
| Yes, we always compare molecular results from CDC with our phenotypic DST for first-line drugs | 30/35 | 86 |
| Sometimes we compare molecular results from CDC with our own phenotypic DST for first-line drugs | 2/35 | 6 |
| No, we report molecular results from CDC without comparing to our own phenotypic DST first-line drugs | 1/35 | 3 |
| Not applicable. We do not perform phenotypic DST for first-line drugs | 2/35 | 6 |
| Reasons for comparing molecular results from CDC’s MDDR with own phenotypic DST for first-line drugs | | |
| Results compared for quality assurance | 27/32 | 84 |
| Results compared to increase understanding of molecular testing | 23/32 | 72 |
| Results are compared to find discordance | 29/32 | 91 |
| Results are compared to prepare for consultation with health care provider or TB control program | 20/32 | 63 |
| Found discordance when molecular results from CDC’s MDDR compared to own phenotypic DST for first-line drugs | | |
| Yes, we found potentially discordant results | 16/32 | 50 |
| No, we have not found any potentially discordant results | 16/32 | 50 |
| Actions taken when discordance found between molecular results from CDC’s MDDR and own phenotypic DST for first-line drugs | | |
| No action taken | 2/16 | 13 |
| Contacted CDC to discuss results | 9/16 | 56 |
| Retested isolate in our laboratory | 10/16 | 63 |
| Withheld sending CDC results to health care provider or TB control | 0/16 | 0 |
| Notified TB control program of potential discordance | 13/16 | 81 |
| Initiated a corrective plan in our laboratory | 1/16 | 6 |
| Referred isolate from patient to another laboratory other than CDC for molecular testing | 0/16 | 0 |
| Action taken dependent on which drug has discordant test results | 2/16 | 13 |
| Comparison of molecular results from CDC’s MDDR with own phenotypic DST for second-line drugs | | |
| Yes, we always compare molecular results from CDC with our phenotypic DST for second-line drugs | 13/35 | 37 |
| Sometimes we compare molecular results from CDC with our own phenotypic DST for second-line drugs | 2/35 | 6 |
| No, we do not perform second-line DST | 20/35 | 57 |
| No, we perform second-line DST but do not compare with molecular results from CDC | 0/35 | 0 |
| Impact on your local phenotypic DST when first available results are molecular results from CDC’s MDDR | | |
| Results have no impact on local phenotypic DST | 24/35 | 69 |
| Local results are discarded | 0/35 | 0 |
| If resistance is indicated by molecular results, isolate is referred to another laboratory other than CDC’s MDDR for additional testing | 3/35 | 9 |
| Other | 8/35 | 23 |
| Observed discordance between the molecular results and the phenotypic DST on the final report from CDC’s MDDR | | |
| Yes, we have observed discordance | 12/35 | 34 |
| No, we have not observed discordance | 20/35 | 57 |
| No, we do not examine CDC’s MDDR results for discordance | 3/35 | 9 |
| Actions taken when discordance observed between molecular results and phenotypic results reported by CDC’s MDDR | | |
| No additional actions taken | 3/12 | 25 |
| Contacted CDC to discuss results | 5/12 | 42 |
| Retested isolate in our laboratory | 6/12 | 50 |
| Withheld sending CDC results to health care provider or TB control | 0/12 | 0 |
| Contacted TB control program to notify them of potential discordance | 10/12 | 83 |
| Referred an isolate from the patient to another laboratory other than CDC for molecular testing | 1/35 | 8 |
| Referred an isolate from the patient to another laboratory other than CDC for phenotypic DST | 1/35 | 8 |
| Action taken dependent on which drug has discordant results | 2/35 | 17 |
| Difficulty interpreting molecular results from CDC’s MDDR | | |
| Results were very difficult to interpret | 0/35 | 0 |
| Results somewhat difficult to interpret | 9/35 | 26 |
| Results were not difficult to interpret | 17/35 | 49 |
| Results were very easy to interpret | 9/35 | 26 |
| Comfort discussing interpretation of molecular results from CDC’s MDDR with health care providers or TB control | | |
| Very comfortable when discussing the results | 23/35 | 66 |
| Had some difficulty discussing the results | 5/35 | 14 |
| In most instances, not contacted for help interpreting the results | 7/35 | 20 |
| Sought help interpreting results from CDC’s MDDR | | |
| Contacted CDC for help interpreting results | 16/35 | 46 |
| Visited CDC website for more information on molecular testing | 5/35 | 14 |
| Consulted with clinician | 2/35 | 6 |
| Did my own research to find information on molecular testing | 7/35 | 20 |
| Contacted local TB program | 5/35 | 14 |
| Contacted Regional Training and Medical Consultation Center (RTMCC) | 1/35 | 3 |
| I did not seek help | 14/35 | 40 |
|
